november 23, 2024

RU/EN

Headings of Vestnik

2015, № 12 (187)

Belyi Y.A., Tereshchenko A.V., Novikov S.V., Shatskikh A.V., Kolesnik S.V., Kolesnik A.I. CLINICAL AND MORPHOLOGICAL INVESTIGATION OF INTRAOCULAR SAFETY OF NEW BIODEGRADABLE IMPLANTThe purpose of researcher is clinical and morphological substantiation of biodegradable implant safety during it's anterior chamber and intravitreal injection. The research was performed on 60 (120 eyes) rabbits chinchilla. Clinical examination, electroretinography and histology with light microscopy were performed after 1, 3, 7, 14, 21, 30 days. To assess the status of intraocular structures prior to implantation and in the dynamics underwent ophthalmic examination: biomicroscopy, photographic registration of fundus images, electroretinography. The results of the study indicates the safety of the intraocular injection of unsaturated and saturated dexamethasone implants.Key words: implant, drug delivery, biodegradable polymer, dexametasone.

Download

References:

1. Nesterov A.P., Basinskij S.N. A new method of administering medicines in the rear section of tennova space. Journal of ophthalmology. 1991; 5: 49-51.

2. Hlusov I.A., Chuchalin V.S., Horuzhaja T.G. Principles for the establishment and operation of drug delivery systems: the manual. Tomsk, Publishing house of Tomsk Polytechnic University: 2008.

3. Horuzhaja T.G. Transport therapeutic delivery system of drugs. Tomsk LLC "Secial":2000.

4. Cardillo J.A., Melo L.A. Jr., Costa R.A. Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology. 2005; 112: 1557–1563.

5. Del Amo E.M., Urtti A. Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug Discov. Today. 2008; 13: 135–143.

6. Desai H. G., Mallery S. R., Schwendeman S. P. Effect of formulation parameters on 2-methoxyestradiol release from injectable cylindrical poly(lactide-coglycolide) implants. Eur. J. Pharm. Biopharm. 2008; 70: 187–198.

7. Dorta M. J., Santovena A., Llabrй M. and et all. Potential applications of PLGA film-implants in modulating in vitro drug release. Int. J. Pharm. 2002; 248: 149–156.

8. Edelhauser H.F., Boatright J.H., Nickerson J.M., and the Third ARVO / Pfizer Research Institute Working Group Drug delivery to posterior intraocular tissues: third annual ARVO/Pfizer ophthalmics research institute conference. Invest. Ophthalmol. Vis. Sci. 2008; 49: 4712–4720.

9. Fowlks W.L. Meridional flow from the corona ciliaris through the pararetinal zone of the rabbit vitreous. Invest. Ophthalmol. Vis. Sci. 1963; 2: 63–71.

10. Frederici T.J. Intravitreal injections: AAO's Focal Points. Clinical Modules for Ophthalmologists. 2009; 27(8): 1–12.

11. Gaudana R., Jwala J., Boddu SH.S. and et. all. Recent perspectives in ocular drug delivery. Pharm Res. 2009; 26: 1197–1216.

12. Ghate D, Edelahauser HF. Ocular drug delivery. Expert Opin. Drug Deliv. 2006: 3: 275–287.

13. Guembel H.O., Krieglsteiner S., Rosenkranz C. and et al. Coplications after implantation of intraocular devices with cytomegalovirus retinitis Graefes. Arch. Clin. Exp. Ophthalmol. 1999; 237: 824–829.

14. Jaffe G. J., Ben-nun J., Guo H. and et. all. Fluocinolone acetonide sustained drug delivery devine to treat severe uveitis. Ophthalmology. 2000: 107(11): 2024–2033.

15. Jaffe G. J., Martin D., Callanan D. and et all. Fluocinolone acetonide implant (retisert) for noninfectious posterior uveitis. Thirty-four-week results of a multicenter randomized clinical study. Ophthalmology. 2006; 113(6): 1020–1027.

15. Jaffe G.J., Ashton P., Pearson P.A. Intraocular drug delivery. Taylor & Francis Group 270 Madison Avenue. — New York, NY 10016: 2006.

16. Jager R.D., Aiello L.P., Patel S.C. and et. all. Risks of intravitreous injection: a comprehensive review. Retina. 2004; 24: 676–698.

17. Kim Y. C. Ocular delivery of macromolecules. Journal of Controlled Release. 2014; 190: 172–181.

18. Lee S.S. Biodegradable implants for sustained drug release in the eye. Pharm. Res. 2010; 27(10): 2043–2053.

19. Luckachan G. E., Pillai C. K. S. Biodegradable polymers-a review on recent trends and emerging perspectives. Journal of Polymers and the Environment. 2011; 19(3): 637–676.

20. Patel A. Ocular drug delivery systems: an overview. World J. Pharmacol. 2013; 2(2): 47–64.

21. Shuwisitkul D. Biodegradable implants with different drug release profiles [dissertation]. Freie Universitдt Berlin, Germany: 2011.

22. Tamaddon L. Design and development of intraocular polymeric implant systems for long-term controlled-release of clindamycin phosphate for toxoplasmic retinochoroiditis. Advanced biomedical research. 2015; 4: 32

23. Tan D.T., Chee S.P., Lim L., Theng J. and et all. Randomized clinical trial of Surodex steroid drug delivery system for cataract surgery: anterior versus posterior placement of two Surodex in the eye. Ophthalmology. 2001; 108: 2172–2181.

24. Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv. Drug Deliv. Rev. 2006; 58(11): 1131–1135.

About this article

Authors: Belyy Yu.A., Shatskih A.V., Tereshchenko A.V., Novikov S.V., Kolesnik S.V., Kolesnik A.I.

Year: 2015

Editor-in-chief

Sergey Aleksandrovich
MIROSHNIKOV

© Электронное периодическое издание: ВЕСТНИК ОГУ on-line (VESTNIK OSU on-line), ISSN on-line 1814-6465
Зарегистрировано в Федеральной службе по надзору в сфере связи, информационных технологий и массовых коммуникаций
Свидетельство о регистрации СМИ: Эл № ФС77-37678 от 29 сентября 2009 г.
Учредитель: Оренбургский государственный университет (ОГУ)
Главный редактор: С.А. Мирошников
Адрес редакции: 460018, г. Оренбург, проспект Победы, д. 13, к. 2335
Тел./факс: (3532)37-27-78 E-mail: vestnik@mail.osu.ru